Zacks Investment Research upgraded shares of Biomerieux (OTCMKTS:BMXMF) from a hold rating to a buy rating in a research report report published on Friday. Zacks Investment Research currently has $103.00 price target on the stock.
According to Zacks, “bioMérieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioMérieux S.A. is based in Marcy L Etoile, France. “
Shares of Biomerieux (BMXMF) opened at $94.90 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.18 and a current ratio of 1.82. Biomerieux has a 12 month low of $78.74 and a 12 month high of $248.00.
COPYRIGHT VIOLATION WARNING: This report was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/29/biomerieux-bmxmf-upgraded-at-zacks-investment-research.html.
bioMérieux SA provides in vitro diagnostics solutions that determine the source of disease and contamination to enhance patient health and consumer safety worldwide. The company offers reagents, instruments, software, and services for diagnosing infectious diseases, healthcare-associated infections, antimicrobial resistance, sepsis, acquired immunodeficiency syndrome, hepatitis, acute care and cardiovascular emergencies, and cancer; and for detecting microorganisms in agri-food, pharmaceutical, biotechnology, and cosmetic products.
Get a free copy of the Zacks research report on Biomerieux (BMXMF)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biomerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerieux and related companies with MarketBeat.com's FREE daily email newsletter.